If you have been reading about clinical endpoint and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2026-01-21. Where a claim depends on a specific study, the study is described rather than over-claimed.
Identity and purity are established by instrumental methods rather than by appearance. Reversed-phase high-performance liquid chromatography separates the peptide from related impurities and yields a purity value, usually expressed as the share of total peak area. Mass spectrometry checks that the observed mass agrees with the mass calculated from the published sequence, while peptide mapping or amino acid analysis adds structural evidence. Water content, counter-ion identity and residual solvents are sometimes reported as well. A certificate of analysis should name the method behind each figure, because results are method-dependent.
Laboratory handling follows the conventions used for other synthetic peptides. Lyophilized material is weighed and dissolved in an aqueous diluent, typically sterile water or bacteriostatic water, using gentle swirling rather than vigorous shaking, because foaming stresses the chain. Solutions are prepared under clean conditions and, where sterility matters, passed through a suitable filter. Working portions are kept small so that stock material is not repeatedly warmed and cooled, a practice that limits both aggregation and gradual loss of activity.
Stability depends strongly on physical state. Dry powder is comparatively robust when held at -20 °C or below, desiccated and shielded from light; under those conditions degradation is slow and measured over years. Once dissolved, the peptide becomes far more vulnerable: backbone hydrolysis, oxidation of susceptible residues and aggregation all proceed faster in solution, and the rates climb with temperature and with pH far from neutral. Refrigerated storage at 2–8 °C extends usable life for short periods, and repeated freeze–thaw cycles are best avoided.
The peptide backbone is chemically modified to resist rapid enzymatic breakdown in the body. A fatty acid side chain promotes binding to serum albumin, which slows renal clearance and supports an extended circulation time. These modifications allow less frequent administration than would be possible with an unmodified peptide. The precise contribution of glucagon receptor activation to the overall metabolic effect remains an area of active investigation, because glucagon raises glucose while also increasing energy expenditure.
Development has progressed through early- and mid-stage human studies in adults with obesity and with type 2 diabetes. Published phase 2 data reported reductions in body weight and improvements in glycemic markers over the treatment period. No regulatory agency has approved the compound for any indication, and it remains available only within controlled research settings. Whether benefits observed in trials translate into durable outcomes after treatment stops is not yet established.
| Property | Value | Notes |
|---|---|---|
| Typical purity specification | 95 per cent or higher by RP-HPLC | Tighter grades reported near 98 per cent |
| Identity confirmation | Mass match by LC-MS | Observed mass compared with sequence-derived mass |
| Storage after dissolution | 2–8 °C, protected from light | Short-term use; avoid repeated freeze–thaw |
| Main degradation routes | Hydrolysis, oxidation, aggregation | Backbone and side-chain susceptibility in solution |
| Common diluents | Sterile water or bacteriostatic water | Choice depends on assay and sterility needs |
Randomized studies of retatrutide measure change in body weight as a percentage of baseline, along with absolute weight loss. Glycemic endpoints include hemoglobin A1c and fasting plasma glucose. Investigators also track blood pressure, lipid fractions, and liver fat content to characterize effects beyond weight alone. Trial designs typically use double-blind, placebo-controlled groups with periodic dose escalation, and they record adverse events throughout both treatment and follow-up periods.
Quantification of the peptide in biological samples generally relies on liquid chromatography coupled with tandem mass spectrometry. This approach separates the analyte from matrix components and detects it by mass-to-charge transitions specific to the molecule. Immunoassays offer higher throughput but can cross-react with related peptides and metabolites, so mass spectrometric methods are preferred when structural confirmation is required. Method validation typically addresses accuracy, precision, selectivity, and stability under handling conditions.
Retatrutide is an investigational synthetic peptide developed under the code LY3437943, with a backbone derived from glucose-dependent insulinotropic polypeptide. Several non-proteinogenic residues, including alpha-aminoisobutyric acid, appear in that backbone, and a fatty diacid side chain attached through a linker extends circulation time. The molecule carries roughly thirty-nine amino acid units and a total mass near 4.7 kilodaltons. Administration is by subcutaneous injection once weekly. Published work uses both the name retatrutide and the code LY3437943.
Pharmacologically the compound activates three receptors: GLP-1, GIP, and glucagon. GLP-1 and GIP signaling contribute to glucose-dependent insulin release, delayed gastric emptying, and reduced appetite, while glucagon receptor activation is associated with increased energy expenditure and hepatic fat oxidation. The single-molecule design is intended to keep these activities in one peptide rather than combining separate agents. Relative activity at each receptor differs, and the balance between them is a central question in interpretation. The glucagon component is partly offset by incretin-mediated insulin secretion, an interaction that remains incompletely characterized.
Development has progressed from single- and multiple-ascending-dose studies in healthy volunteers into larger randomized trials in adults with obesity, type 2 diabetes, and fatty liver disease. Early reports describe dose-dependent reductions in body weight and improvements in glycemic markers over treatment periods of several months. Whether the glucagon arm adds tolerability cost without added benefit is still debated. Long-term cardiovascular outcomes, effects after treatment stops, and performance in older or comorbid populations are open questions rather than settled findings. Approval status may change, so the current investigational label should be confirmed against regulatory sources.
=== Deformed nuclei === Though nuclei within the island of stability around N = 184 are predicted to be spherical, studies from the early 1990s—beginning with Polish physicists Zygmunt Patyk and Adam Sobiczewski in 1991—suggest that some superheavy elements do not have perfectly spherical nuclei. A change in the shape of the nucleus changes the position of neutrons and protons in the shell. Research indicates that large nuclei farther from spherical magic numbers are deformed, causing magic numbers to shift or new magic numbers to appear. Current theoretical investigation indicates that in the region Z = 106–108 and N ≈ 160–164, nuclei may be more resistant to fission as a consequence of shell effects for deformed nuclei; thus, such superheavy nuclei would only undergo alpha decay. Hassium-270 is now believed to be a doubly magic deformed nucleus, with deformed magic numbers Z = 108 and N = 162. It has a half-life of 9 seconds. This is consistent with models that take into account the deformed nature of nuclei intermediate between the actinides and island of stability near N = 184, in which a stability "peninsula" emerges at deformed magic numbers Z = 108 and N = 162. Determination of the decay properties of neighboring hassium and seaborgium isotopes near N = 162 provides further strong evidence for this region of relative stability in deformed nuclei.
The imprinted image turned out to be wash-resistant, impervious to temperatures of 250 °C (482 °F) and was undamaged by exposure to a range of harsh chemicals, including bisulphite, which, without the gelatine, would normally have degraded ferric oxide to the compound ferrous oxide. Instead of painting, it has been suggested that the bas-relief could also be heated and used to scorch an image onto the cloth. However researcher Thibault Heimburger performed some experiments with the scorching of linen, and found that a scorch mark is only produced by direct contact with the hot object—thus producing an all-or-nothing discoloration with no graduation of color as is found in the shroud.
=== Research and safety === G. biloba and its extracts are not approved drugs in the United States and do not have sufficient clinical evidence for uses as a therapy, according to a 2023 review. The United States National Center for Complementary and Integrative Health concludes that, despite extensive research, ginkgo has never been conclusively proven effective for any health condition, including dementia, cognitive decline, or other disorders for which it is commonly marketed. Although extracts of G. biloba leaf are often marketed to consumers as cognitive enhancers, there is no high-quality, peer-reviewed evidence supporting its use for memory or attention improvement in healthy people, as of February 2026. Systematic reviews have found no evidence for effectiveness of ginkgo extract in treating high blood pressure, menopause-related cognitive dysfunction, tinnitus, post-stroke recovery, or altitude sickness. A 2026 Cochrane review found that G. biloba shows little to no meaningful benefit for mild cognitive impairment or subjective complaints, uncertain or minimal effects in multiple sclerosis-related cognitive issues, and small to moderate, low-certainty improvements in dementia symptoms, with generally similar safety to placebo. Although a 2021 umbrella review concluded that G. biloba may be useful and safe for improving cognitive function and daily living activities in people with Alzheimer's disease, a 2023 analysis concluded there is insufficient evidence to support its use in Alzheimer's therapy. A 2016 systematic review concluded that G.
Glyceroneogenesis is a metabolic pathway which synthesizes glycerol 3-phosphate (used to form triglycerides) from precursors other than glucose. Usually, glycerol 3-phosphate is generated from glucose by glycolysis, in the liquid of the cell's cytoplasm (the cytosol). Glyceroneogenesis is used when the concentrations of glucose in the cytosol are low, and typically uses pyruvate as the precursor, but can also use alanine, glutamine, or any substances from the TCA cycle. The main regulator enzyme for this pathway is an enzyme called phosphoenolpyruvate carboxykinase (PEPC-K), which catalyzes the decarboxylation of oxaloacetate to phosphoenolpyruvate. Glyceroneogenesis is observed mainly in adipose tissue, and in the liver. A significant biochemical pathway regulates cytosolic lipid levels. Intense suppression of glyceroneogenesis may lead to metabolic disorders such as type 2 diabetes.
Sources: en.wikipedia.org
Brown fat in humans in the scientific and popular literature refers to two cell populations defined by both anatomical location and cellular morphology. Both share the presence of small lipid droplets and numerous iron-rich mitochondria, giving the brown appearance.
== Causes == The etiology, or causes, of BPD involves several causes, with no consensus on a single one. BPD may share a connection with post-traumatic stress disorder (PTSD), with both having a traumatic substrate. While childhood trauma is a recognized contributing factor, the roles of congenital brain abnormalities, genetics, neurobiology, and non-traumatic environmental factors remain subjects of ongoing investigation.
==== Rewiring cortex ==== Sur’s work on cortical plasticity has had a seminal impact on the field. His discovery of developmental plasticity induced by novel input activity overturned an innate ‘labeled line’ hypothesis of cortical function. By routing visual inputs to the auditory thalamus in neonatal ferrets, his lab showed that the auditory cortex, which normally processes hearing, can ‘rewire’ its circuits to generate visual maps, process vision, and mediate visual behavior . These discoveries provide a powerful demonstration that cortex is a reconfigurable substrate that can be patterned by inputs.
Sources: en.wikipedia.org
Feathers are one of the most recognizable characteristics of modern birds, and a trait that was also shared by several non-avian dinosaurs. Based on the current distribution of fossil evidence, it appears that feathers were an ancestral dinosaurian trait, though one that may have been selectively lost in some species. Direct fossil evidence of feathers or feather-like structures has been discovered in a diverse array of species in many non-avian dinosaur groups, both among saurischians and ornithischians. Simple, branched, feather-like structures are known from heterodontosaurids, primitive neornithischians, and theropods, and primitive ceratopsians. Evidence for true, vaned feathers similar to the flight feathers of modern birds has been found only in the theropod subgroup Maniraptora, which includes oviraptorosaurs, troodontids, dromaeosaurids, and birds. Feather-like structures known as pycnofibres have also been found in pterosaurs. However, researchers do not agree on whether these structures share a common origin between lineages (i.e., they are homologous), or if they were the result of widespread experimentation with skin coverings among ornithodirans. If the former is the case, filaments may have been common in the ornithodiran lineage and evolved before the appearance of dinosaurs themselves. Research into the genetics of American alligators has revealed that crocodylian scutes do possess feather-keratins during embryonic development, but these keratins are not expressed by the animals before hatching.
Interactive tutorial on mass spectra National High Magnetic Field Laboratory Mass spectrometer simulation An interactive application simulating the console of a mass spectrometer Realtime Mass Spectra simulation Tool to simulate mass spectra in the browser
=== Highly controllable properties === Porous silicon studies conducted in 1995 showed that the behaviour of porous silicon can be altered in between "bio-inert", "bioactive" and "resorbable" by varying the porosity of the silicon sample. The in-vitro study used simulated body fluid containing ion concentration similar to the human blood and tested the activities of porous silicon sample when exposed to the fluids for prolonged period of time. It was found that high porosity mesoporous layers were completely removed by the simulated body fluids within a day. In contrast, low to medium porosity microporous layers displayed more stable configurations and induced hydroxyapatite growth.
Sources: en.wikipedia.org
Purity is normally given as a percentage from reversed-phase HPLC, calculated as the main peak area relative to total peak area. Research-grade material is commonly specified at 95 per cent or higher, with tighter specifications available. The number is method-dependent and should be read alongside the chromatogram.
Mass spectrometry is the standard check, comparing the measured mass with the mass calculated from the published amino acid sequence. Retention time on HPLC and peptide mapping provide supporting evidence. Sequence-level confirmation separates it from closely related analogues.
Dry powder is chemically stable enough for freezer storage over long periods. In solution, water participates directly in hydrolysis and enables aggregation, so breakdown accelerates. Cold, dark, short-term storage after dissolution reflects that difference.
Retatrutide is an investigational synthetic peptide that activates three metabolic receptors: GLP-1, GIP, and glucagon. It is being studied for obesity and type 2 diabetes. It has not been approved for clinical use.